Take a look at our previous reports:

The Galapagos Shares in 2024

Galapagos NV (ticker: GLPG) has been listed on Euronext Amsterdam and Brussels since May 6, 2005 and on the Nasdaq Global Select Market since May 14, 2015. In 2024, Galapagos NV was part of the BEL20 index (top 20 listed companies) on Euronext Brussels, the AMX Index (Amsterdam Midcap-index) on Euronext Amsterdam, and the NBI (Nasdaq Biotechnology Index) on Nasdaq in New York.

The Galapagos Share in 2024

The Galapagos Share in 2024 (graphic)

In 2024, the average daily trading volume on Euronext was 89,108 shares and €2.5 million turnover. The daily trading volume on Nasdaq in 2024 was 152,282 American Depository Shares (ADSs) and $4.5 million turnover.

Galapagos vs Next Biotech Index in 2024

Galapagos vs Next Biotech Index in 2024 (graphic)

Galapagos vs Nasdaq Biotechnology Index in 2024

Galapagos vs Nasdaq Biotechnology Index in 2024 (graphic)

Investor Relations Activities

17 analysts cover the Galapagos stock.

Our IR team participated in 9 investor conferences in Europe and the U.S. in 2024. Several broker-organized and self-organized roadshows and (virtual) meetings were held throughout the U.S. and Europe, during which we held approximately 242 investor meetings. We organized webcasts to present our 2023 Full Year, and our 2024 Q1, Half Year, and Q4 results.

The main topics of discussion with investors in 2024 included progress of our pipeline and lead candidates, data presented at ASH, the FDA IND clearance of the ATALANTA study, our oral presentation and showcase on GLPG5101 at ASH, new collaboration agreements and news related to Board appointments and departures.

Our major shareholders as of December 31, 2024 are provided in the chart below:

Our major shareholders as of December 31, 2024  (graphic)
FDA
The U.S. Food and Drug Administration is an agency responsible for protecting and promoting public health and in charge of American market approval of new medications
GLPG5101
A second generation anti-CD19/4-1BB CAR-T product candidate currently in Phase 1/2 study in multiple aggressive B-cell malignancies
Investigational New Drug (IND) Application
United States Federal law requires a pharmaceutical company to obtain an exemption to ship an experimental drug across state lines, usually to clinical investigators, before a marketing application for the drug has been approved. The IND is the means by which the sponsor obtains this exemption, allowing them to perform clinical studies